ICO.V - iCo Therapeutics Inc.
| Previous Close | 0.0450 |
| Open | 0.0400 |
| Bid | 0.0400 x 0 |
| Ask | 0.0450 x 0 |
| Day's Range | 0.0350 - 0.0450 |
| 52 Week Range | 0.0200 - 0.1400 |
| Volume | 4,439,700 |
| Avg. Volume | 548,162 |
| Market Cap | 6.15M |
| Beta (5Y Monthly) | 3.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0140 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
iCo Therapeutics Announces Leadership Changes
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") announces that Andrew Rae, MBA, has resigned from his roles as both President & CEO and Director. Mr. Rae has agreed to assist management, through to the end of the fiscal quarter, to ensure a smooth and orderly transition.iCo also announces today that Susan Koppy will immediately assume the role of ...
- Newsfile
iCo Therapeutics Successfully Concludes Phase 1b Clinical Study Announces Positive Primary End Point for Oral Amphotericin B
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today a positive primary endpoint with respect to its Phase 1b Oral Amphotericin B (Oral Amp B) study. In the Phase 1b study all repeat doses were well-tolerated, with no serious adverse events. There were no signs of kidney or other toxicities. Dr. Peter Hnik, ...
- Newsfile
iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow Up
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in its Phase 1b study have received doses of Oral Amphotericin B (either 100mg and 400mg/day) over ten days and, subsequent to dosing, have been followed up for an additional ten days. Full results of the Phase 1b study are currently ...
- Simply Wall St.
Is iCo Therapeutics (CVE:ICO) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Newsfile
iCo Therapeutics Announces Option Grants
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today granted 2,000,000 stock options to directors, officers and an advisor.The stock options are exercisable at the price of $0.08 and will expire on January 10, 2025. The stock options shall vest as follows: 1/5 on today's date (the "Effective Date") and then 1/5 every six months until all options are vested. The closing ...
- Newsfile
iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects
Vancouver, British Columbia--(Newsfile Corp. - December 24, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in the first of two cohorts in its Phase 1b study have received 100 mg doses of Oral Amphotericin B on a daily basis over ten days, with no drug-related adverse events observed to date. One additional cohort is expected ...
- Newsfile
iCo Therapeutics Engages Ora for iCo-008 Ophthalmic Strategy and Pre Phase II FDA Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") today announced it has engaged Ora, Inc., the world's leading full-service ophthalmic CRO and product development firm, to assist the Company with its ophthalmic regulatory and development strategy for iCo-008. It is expected that this work will ultimately result in a meeting with the FDA prior to initiation of a Phase 2 trial. Ora ...
- Newsfile
iCo Therapeutics Announces Dosing of First Full Cohort in Second Oral Amphotericin B Study
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in the first of two cohorts in its Phase 1b study have received the first dose of Oral Amphotericin B. Dosing will occur over a period of ten days. One additional cohort is expected to be dosed in Q1 2020, ...
- Newsfile
iCo Therapeutics Announces Third Quarter 2019 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the Quarter ended September 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "Several important milestones have been achieved in recent weeks with ethics approval to enter our second oral Amphotericin B ("Oral ...
- Newsfile
Alexion Pharmaceuticals - iCo's New Partner for the Development and Commercialization of iCo-008
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced today that the purchase of the assets of Immune Pharmaceuticals ("Immune"), including the sublicense of iCo-008, by Alexion Pharmaceuticals, Inc. ("Alexion") has received all requisite court approvals and the closing of the purchase transaction is expected prior to the end of Q1 2020. Alexion has assumed Immune's rights and obligations under the ...
- Newsfile
iCo Therapeutics Inc. Provides an Update Regarding Oral Amphotericin Study, Marketing and Partnering Activities
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its Australian subsidiary, iCo Therapeutics Pty Ltd., today announced several developments related to its wholly-owned oral Amphotericin B (Oral Amp B) asset and current marketing and partnering efforts.Oral Amphotericin B ("Oral Amp B") Clinical Program:Currently iCo and its partner contract research organizations ("CROs") expect dosing of the first full cohort of subjects this ...
- Newsfile
Monoclonal Antibodies; A Growing Sector of the Bio/Pharma Industry and How Smaller Players are Finding a Niche
Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - October 28, 2019) - Investorideas.com, a leading investor news resource covering pharmaceutical and biotech stocks releases a sector snapshot reporting on the growth of the global monoclonal antibody market and how this is affecting industry decisions moving forward. Why is this a sector to pay attention to? According to recent industry reports, "The Monoclonal Antibodies market worldwide is projected to grow by US$47.6 Billion, driven ...
- Newsfile
iCo Therapeutics Inc. Provides a Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2019) - iCo Therapeutics Inc. ("iCo" or "the Company") (TSXV: ICO) (OTCQB: ICOTF) today announced several corporate developments.iCo has been monitoring a current US court-mandated auction process, with respect to systemic uses of Bertilimumab, previously sublicensed to Immune Pharmaceuticals. On October 21, 2019, the bankruptcy court in New Jersey approved a sale order relating to the assignment of the sublicense of iCo's assets to Alexion Pharmaceuticals. With ...
- Newsfile
iCo Therapeutics Announces Second Quarter 2019 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the Quarter ended June 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc.,"Q2 efforts were significant in laying a foundation for the corporate milestones we expect in late 2019 and ...
- Newsfile
iCo Therapeutics Inc. Announces the Issuance of 41,200,000 Units Pursuant to its Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued 41,200,000 units ("Units") pursuant to a non-brokered private placement (the "Private Placement"). The Units were sold at a price of $0.05 per Unit, for aggregate gross proceeds to the Company of $2,060,000. Each Unit issued pursuant to the Private Placement consists of one common share ...
- Newsfile
iCo Therapeutics Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today provided an update with respect to the Company's clinical and regulatory path for its Oral Amphotericin B (Oral Amp B) candidate. During Q2 2019, iCo submitted a plan and further additional materials to an Australian IRB (Institutional Review Board) outlining a proposed multi-center study of up to 90 individuals comparing Oral Amp B to ...
- Simply Wall St.
Imagine Owning iCo Therapeutics (CVE:ICO) And Wondering If The 38% Share Price Slide Is Justified
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
- Newsfile
iCo Therapeutics Announces AGM Voting Results
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the results of voting at its 2019 Annual General Meeting of Shareholders held on June 27, 2019.A total of 20,801,184 common shares were voted in connection with the meeting, representing approximately 19% of the issued and outstanding common shares of the company. Shareholders voted as follows:MotionVoted For% Voted ForVotes Withheld% Votes WithheldAppointment ...
- Newsfile
iCo Therapeutics Announces First Quarter 2019 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the Quarter ended March 31, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "during the first quarter we were able to close a financing with several healthcare focused institutional investors, in ...
- Newsfile
iCo Therapeutics Announces 2018 Year End Financial Results
Vancouver, British Columbia--(Newsfile Corp. - April 30, 2019) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "2018 represented a year of significant advances as we entered into a clinical trial for Oral Amphotericin B ...
